Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Cancer Drug Targets
  4. Fast Track Articles
  5. Fast Track Article
image of Zinc Finger Protein 536 is a Potential Prognostic Biomarker that Promotes Neuroblastoma Progression via VEGFR2-PI3K-AKT Pathway

Abstract

Background

Neuroblastoma (NB) is a well-known pediatric malignancy intertwined with neurodevelopment. Previously implicated in neuronal differentiation, Zinc Finger Protein 536 (ZNF536) has emerged as a promising prognostic and immune-related biomarker in our pan-cancer analysis.

Methods

Single-cell RNA transcriptome sequencing, bulk transcriptome analysis, and immunohistochemistry were used to assess ZNF536 expression and its association with prognosis. Cell proliferation, migration, invasion, and differentiation in ZNF536-knockdown NB cell lines were detected to evaluate the effect of ZNF536 on tumor cells. Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), a potential target of ZNF536, and its downstream PI3K/AKT signaling cascade were investigated using transcriptome sequencing, CUT&Tag, quantitative real-time PCR (qRT-PCR), and Western blotting. The role of ZNF536 in tumorigenesis and the potential regulation axis was evaluated using a BALB/c nude mouse xenograft tumor model.

Results

ZNF536 mRNA and protein expression were significantly higher in NB patients with poor prognosis. , ZNF536 knockdown curtailed proliferation, migration, and invasion of NB cells while fostering differentiation. ZNF536 regulated VEGFR2 expression, thus activating the PI3K-AKT pathway. , ZNF536 knockdown reduced tumor growth and proliferation via the VEGFR2-PI3K-AKT pathway.

Conclusion

ZNF536 resulted as a novel prognostic biomarker in NB, promoting oncogenesis through VEGFR2-PI3K-AKT signaling axis modulation, suggesting its therapeutic potential in managing NB progression.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096332753240913104409
2024-10-15
2025-01-29

  • From This Site

    /content/journals/ccdt/10.2174/0115680096332753240913104409
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Maris J.M. Recent advances in neuroblastoma. N. Engl. J. Med. 2010 362 23 2202 2211 10.1056/NEJMra0804577 20558371
    [Google Scholar]
  2. Newman E.A. Nuchtern J.G. Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies. Semin. Pediatr. Surg. 2016 25 5 257 264 10.1053/j.sempedsurg.2016.09.007 27955728
    [Google Scholar]
  3. Tsubota S. Kadomatsu K. Origin and initiation mechanisms of neuroblastoma. Cell Tissue Res. 2018 372 2 211 221 10.1007/s00441‑018‑2796‑z 29445860
    [Google Scholar]
  4. Schulte J.H. Eggert A. Neuroblastoma. Crit. Rev. Oncog. 2015 20 3-4 245 270 10.1615/CritRevOncog.2015014033 26349419
    [Google Scholar]
  5. Mahapatra S. Challagundla K.B. Neuroblastoma. StatPearls. StatPearls Publishing 2024
    [Google Scholar]
  6. Sokol E. Desai A.V. Applebaum M.A. Valteau-Couanet D. Park J.R. Pearson A.D.J. Schleiermacher G. Irwin M.S. Hogarty M. Naranjo A. Volchenboum S. Cohn S.L. London W.B. Age, diagnostic category, tumor grade, and mi-tosis-karyorrhexis index are independently prognostic in neu-roblastoma: An INRG project. J. Clin. Oncol. 2020 38 17 1906 1918 10.1200/JCO.19.03285 32315273
    [Google Scholar]
  7. Brodeur G.M. Spontaneous regression of neuroblastoma. Cell Tissue Res. 2018 372 2 277 286 10.1007/s00441‑017‑2761‑2 29305654
    [Google Scholar]
  8. Davidoff A.M. Neuroblastoma. Semin. Pediatr. Surg. 2012 21 1 2 14 10.1053/j.sempedsurg.2011.10.009 22248965
    [Google Scholar]
  9. Sharma R. Mer J. Lion A. Vik T.A. Clinical presentation, evaluation, and management of neuroblastoma. Pediatr. Rev. 2018 39 4 194 203 10.1542/pir.2017‑0087 29610427
    [Google Scholar]
  10. Basta N.O. Halliday G.C. Makin G. Birch J. Feltbower R. Bown N. Elliott M. Moreno L. Barone G. Pearson A.D.J. James P.W. Tweddle D.A. McNally R.J.Q. Factors associated with recurrence and survival length following re-lapse in patients with neuroblastoma. Br. J. Cancer 2016 115 9 1048 1057 10.1038/bjc.2016.302 27701387
    [Google Scholar]
  11. Cheung N.K.V. Dyer M.A. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat. Rev. Cancer 2013 13 6 397 411 10.1038/nrc3526 23702928
    [Google Scholar]
  12. Yu A.L. Gilman A.L. Ozkaynak M.F. London W.B. Kreissman S.G. Chen H.X. Smith M. Anderson B. Villa-blanca J.G. Matthay K.K. Shimada H. Grupp S.A. Seeger R. Reynolds C.P. Buxton A. Reisfeld R.A. Gillies S.D. Cohn S.L. Maris J.M. Sondel P.M. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblas-toma. N. Engl. J. Med. 2010 363 14 1324 1334 10.1056/NEJMoa0911123 20879881
    [Google Scholar]
  13. Del Bufalo F. De Angelis B. Caruana I. Del Baldo G. De Ioris M.A. Serra A. Mastronuzzi A. Cefalo M.G. Pagli-ara D. Amicucci M. Li Pira G. Leone G. Bertaina V. Sinibaldi M. Di Cecca S. Guercio M. Abbaszadeh Z. Iaffaldano L. Gunetti M. Iacovelli S. Bugianesi R. Mac-chia S. Algeri M. Merli P. Galaverna F. Abbas R. Gar-ganese M.C. Villani M.F. Colafati G.S. Bonetti F. Rabusin M. Perruccio K. Folsi V. Quintarelli C. Locatelli F. GD2-CART01 for Relapsed or Refractory High-Risk Neu-roblastoma. N. Engl. J. Med. 2023 388 14 1284 1295 10.1056/NEJMoa2210859 37018492
    [Google Scholar]
  14. Heczey A. Xu X. Courtney A.N. Tian G. Barragan G.A. Guo L. Amador C.M. Ghatwai N. Rathi P. Wood M.S. Li Y. Zhang C. Demberg T. Di Pierro E.J. Sher A.C. Zhang H. Mehta B. Thakkar S.G. Grilley B. Wang T. Weiss B.D. Montalbano A. Subramaniam M. Xu C. Sa-char C. Wells D.K. Dotti G. Metelitsa L.S. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: up-dated phase 1 trial interim results. Nat. Med. 2023 29 6 1379 1388 10.1038/s41591‑023‑02363‑y 37188782
    [Google Scholar]
  15. Zhang J. Webster S. Duffin B. Bernstein M.N. Steill J. Swanson S. Forsberg M.H. Bolin J. Brown M.E. Majum-der A. Capitini C.M. Stewart R. Thomson J.A. Slukvin I.I. Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies. Stem Cell Reports 2023 18 2 585 596 10.1016/j.stemcr.2022.12.012 36638788
    [Google Scholar]
  16. Al-Ghabkari A. Narendran A. In vitro Characterization of a Potent p53-MDM2 Inhibitor, RG7112 in Neuroblastoma Can-cer Cell Lines. Cancer Biother. Radiopharm. 2019 34 4 252 257 10.1089/cbr.2018.2732 30724592
    [Google Scholar]
  17. Kushner B.H. Cheung N.K.V. Modak S. Becher O.J. Basu E.M. Roberts S.S. Kramer K. Dunkel I.J. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: L ong‐term progression‐free survival of patients with resistant neuroblastoma. Int. J. Cancer 2017 140 2 480 484 10.1002/ijc.30440 27649927
    [Google Scholar]
  18. Goldsmith K.C. Park J.R. Kayser K. Malvar J. Chi Y.Y. Groshen S.G. Villablanca J.G. Krytska K. Lai L.M. Acharya P.T. Goodarzian F. Pawel B. Shimada H. Ghaza-rian S. States L. Marshall L. Chesler L. Granger M. De-sai A.V. Mody R. Morgenstern D.A. Shusterman S. Ma-cy M.E. Pinto N. Schleiermacher G. Vo K. Thurm H.C. Chen J. Liyanage M. Peltz G. Matthay K.K. Berko E.R. Maris J.M. Marachelian A. Mossé Y.P. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat. Med. 2023 29 5 1092 1102 10.1038/s41591‑023‑02297‑5 37012551
    [Google Scholar]
  19. Peirce S.K. Findley H.W. Prince C. Dasgupta A. Cooper T. Durden D.L. The PI-3 kinase-Akt-MDM2-survivin sig-naling axis in high-risk neuroblastoma: a target for PI-3 ki-nase inhibitor intervention. Cancer Chemother. Pharmacol. 2011 68 2 325 335 10.1007/s00280‑010‑1486‑7 20972874
    [Google Scholar]
  20. Bergaggio E. Tai W.T. Aroldi A. Mecca C. Landoni E. Nüesch M. Mota I. Metovic J. Molinaro L. Ma L. Al-varado D. Ambrogio C. Voena C. Blasco R.B. Li T. Klein D. Irvine D.J. Papotti M. Savoldo B. Dotti G. Chi-arle R. ALK inhibitors increase ALK expression and sensi-tize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell 2023 41 12 2100 2116.e10 10.1016/j.ccell.2023.11.004 38039964
    [Google Scholar]
  21. Perwein T. Lackner H. Sovinz P. Benesch M. Schmidt S. Schwinger W. Urban C. Survival and late effects in chil-dren with stage 4 neuroblastoma. Pediatr. Blood Cancer 2011 57 4 629 635 10.1002/pbc.23036 21319289
    [Google Scholar]
  22. Tsubota S. Kadomatsu K. Origin and mechanism of neuro-blastoma. Oncoscience 2017 4 7-8 70 72 10.18632/oncoscience.360 28966937
    [Google Scholar]
  23. Dong R. Yang R. Zhan Y. Lai H.D. Ye C.J. Yao X.Y. Luo W.Q. Cheng X.M. Miao J.J. Wang J.F. Liu B.H. Liu X.Q. Xie L.L. Li Y. Zhang M. Chen L. Song W.C. Qian W. Gao W.Q. Tang Y.H. Shen C.Y. Jiang W. Chen G. Yao W. Dong K.R. Xiao X.M. Zheng S. Li K. Wang J. Single-Cell Characterization of Malignant Phenotypes and Developmental Trajectories of Adrenal Neuroblastoma. Cancer Cell 2020 38 5 716 733.e6 10.1016/j.ccell.2020.08.014 32946775
    [Google Scholar]
  24. Qin Z. Ren F. Xu X. Ren Y. Li H. Wang Y. Zhai Y. Chang Z. ZNF536, a novel zinc finger protein specifically expressed in the brain, negatively regulates neuron differen-tiation by repressing retinoic acid-induced gene transcription. Mol. Cell. Biol. 2009 29 13 3633 3643 10.1128/MCB.00362‑09 19398580
    [Google Scholar]
  25. wu; Wang, S.J.; Wu, Q. Comprehensive Analysis of Biologic and Prognostic Implication for ZNF536 in Pan-Cancer. Eura-sian Journal of Medicine and Oncology 2023 7 2 143 159 10.14744/ejmo.2023.29445
    [Google Scholar]
  26. Cheng T. Ying M. Antitumor Effect of Saikosaponin A on Human Neuroblastoma Cells. BioMed Res. Int. 2021 2021 1 12 10.1155/2021/5845554 34513994
    [Google Scholar]
  27. Li J. Wang X. Li Z. Li M. Zheng X. Zheng D. Wang Y. Xi M. SULF1 Activates the VEGFR2/PI3K/AKT Pathway to Promote the Development of Cervical Cancer. Curr. Cancer Drug Targets 2023 10.2174/1568009623666230804161607 37539927
    [Google Scholar]
  28. Song F. Hu B. Cheng J.W. Sun Y.F. Zhou K.Q. Wang P.X. Guo W. Zhou J. Fan J. Chen Z. Yang X.R. Anlo-tinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarci-noma. Cell Death Dis. 2020 11 7 573 10.1038/s41419‑020‑02749‑7 32709873
    [Google Scholar]
  29. Zafar A. Wang W. Liu G. Wang X. Xian W. McKeon F. Foster J. Zhou J. Zhang R. Molecular targeting therapies for neuroblastoma: Progress and challenges. Med. Res. Rev. 2021 41 2 961 1021 10.1002/med.21750 33155698
    [Google Scholar]
  30. Wang X. Bove A.M. Simone G. Ma B. Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathologi-cal Role. Front. Cell Dev. Biol. 2020 8 599281 10.3389/fcell.2020.599281 33304904
    [Google Scholar]
  31. Wang H. Wang X. Xu L. Chromosome 1p36 candidate gene ZNF436 predicts the prognosis of neuroblastoma: a bio-informatic analysis. Ital. J. Pediatr. 2023 49 1 145 10.1186/s13052‑023‑01549‑x 37904225
    [Google Scholar]
  32. Pieraccioli M. Nicolai S. Pitolli C. Agostini M. Antonov A. Malewicz M. Knight R.A. Raschellà G. Melino G. ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma. Proc. Natl. Acad. Sci. USA 2018 115 28 7356 7361 10.1073/pnas.1801435115 29941555
    [Google Scholar]
  33. Sartelet H. Rougemont A.L. Fabre M. Castaing M. Duval M. Fetni R. Michiels S. Beaunoyer M. Vassal G. Activa-tion of the phosphatidylinositol 3′-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1. Hum. Pathol. 2011 42 11 1727 1739 10.1016/j.humpath.2011.01.019 21641013
    [Google Scholar]
  34. Qiao J. Lee S. Paul P. Qiao L. Taylor C.J. Schlegel C. Colon N.C. Chung D.H. Akt2 regulates metastatic potential in neuroblastoma. PLoS One 2013 8 2 e56382 10.1371/journal.pone.0056382 23468863
    [Google Scholar]
  35. Zaghloul N. Hernandez S.L. Bae J.O. Huang J. Fisher J.C. Lee A. Kadenhe-Chiweshe A. Kandel J.J. Yamashiro D.J. Vascular endothelial growth factor blockade rapidly elic-its alternative proangiogenic pathways in neuroblastoma. Int. J. Oncol. 2009 34 2 401 407 19148474
    [Google Scholar]
  36. He Y. Sun M.M. Zhang G.G. Yang J. Chen K.S. Xu W.W. Li B. Targeting PI3K/Akt signal transduction for can-cer therapy. Signal Transduct. Target. Ther. 2021 6 1 425 10.1038/s41392‑021‑00828‑5 34916492
    [Google Scholar]
  37. Ponzoni M. Bachetti T. Corrias M.V. Brignole C. Pasto-rino F. Calarco E. Bensa V. Giusto E. Ceccherini I. Per-ri P. Recent advances in the developmental origin of neuro-blastoma: an overview. J. Exp. Clin. Cancer Res. 2022 41 1 92 10.1186/s13046‑022‑02281‑w 35277192
    [Google Scholar]
  38. Furlan A. Adameyko I. Schwann cell precursor: a neural crest cell in disguise? Dev. Biol. 2018 444 Suppl. 1 S25 S35 10.1016/j.ydbio.2018.02.008 29454705
    [Google Scholar]
  39. Solovieva T. Bronner M. Schwann cell precursors: Where they come from and where they go. Cells & Development 2021 166 203686 10.1016/j.cdev.2021.203686 33994354
    [Google Scholar]
  40. Zhao J. Wen D. Zhang S. Jiang H. Di X. The role of zinc finger proteins in malignant tumors. FASEB J. 2023 37 9 e23157 10.1096/fj.202300801R 37615242
    [Google Scholar]
  41. Li X. Han M. Zhang H. Liu F. Pan Y. Zhu J. Liao Z. Chen X. Zhang B. Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcino-ma. Biomark. Res. 2022 10 1 2 10.1186/s40364‑021‑00345‑1 35000617
    [Google Scholar]
  42. Cassandri M. Smirnov A. Novelli F. Pitolli C. Agostini M. Malewicz M. Melino G. Raschellà G. Zinc-finger pro-teins in health and disease. Cell Death Discov. 2017 3 1 17071 10.1038/cddiscovery.2017.71 29152378
    [Google Scholar]
  43. Ichikawa D.M. Abdin O. Alerasool N. Kogenaru M. Mueller A.L. Wen H. Giganti D.O. Goldberg G.W. Ad-ams S. Spencer J.M. Razavi R. Nim S. Zheng H. Gion-co C. Clark F.T. Strokach A. Hughes T.R. Lionnet T. Taipale M. Kim P.M. Noyes M.B. A universal deep-learning model for zinc finger design enables transcription factor reprogramming. Nat. Biotechnol. 2023 41 8 1117 1129 10.1038/s41587‑022‑01624‑4 36702896
    [Google Scholar]
/content/journals/ccdt/10.2174/0115680096332753240913104409
Loading
Zinc Finger Protein 536 is a Potential Prognostic Biomarker that Promotes Neuroblastoma Progression via VEGFR2-PI3K-AKT Pathway
Bentham Science Publishers ; https://doi.org/10.2174/0115680096332753240913104409
/content/journals/ccdt/10.2174/0115680096332753240913104409
/content/journals/ccdt/10.2174/0115680096332753240913104409
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Research Article
Keywords: VEGFR2 ; ZNF536 ; Neuroblastoma ; pediatric oncology ; prognostic biomarker ; PI3K-AKT signaling

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test